No Data
Rating information (investment determination change - Part 1) = Trial, Air Water ETC.
◎ Daiwa Securities (5 levels: 1 > 2 > 3 > 4 > 5) Trial <141A.T> -- New "2", 3,300 yen. ◎ SMBC Nikko Securities (3 levels: 1 > 2 > 3) Air Water <4088.T> -- New "1", 2,430 yen. Japan Oxygen HD <4091.T> -- New "2", 4,390 yen. ◎ Mizuho Securities (3 levels: Buy > Hold > underperform) Matsukaze <7979.T> -- New "Buy", 3,300 yen. Fukuda Electric <6960.T> -- Resuming "Hold", 6,900 yen. Provided by:
《Rating Change Observation》 Upgraded new and Matsukaze / Sumitomo Rubbers, NINTENDO CO LTD downgraded, etc.
◎ New and resumed trials <141A.T> -- A domestic major ranks second in five levels: Kioxia <285A.T> -- Bank-related ranks in the middle of three levels: Air Water <4088.T> -- A domestic major ranks at the top of three levels: Japan Oxygen HD <4091.T> -- A domestic major ranks in the middle of three levels: Fukuda Electric <6960.T> -- Bank-related ranks in the middle of three levels: Hotonics <6965.T> -- A domestic medium-sized company ranks at the top of three levels (during trading) IHI <7013.T> -- A foreign company ranks at the top of three levels.
Fukuda Electric, Cyberdyne, etc. (additional) Rating
Upgrade - Bullish code Stock Company Name Securities Company Conventional Changes After----------------------------------------------------------------<2331> ALSOK Morgan S 'Equal W' 'Over W' Downgrade - Bearish code Stock Company Name Securities Company Conventional Changes After----------------------------------------------------------------
Fukuda Denshi: Half Year Report - Term 78 (2024/04/01 - 2025/03/31)
FMR LLC decrases its stake in Fukuda Denshi(6960.JP) to 5.02%
On Nov 8, FMR LLC submitted the Change Report to Ministry of Finance. The report shows that FMR LLC decreased their holdings in $Fukuda Denshi(6960.JP)$, with their joint shareholding ratio down
Canon Inc-spons adr, 3Q operating profit increased by 14.4% to 296.6 billion yen.
Canon Inc-Spons ADR <7751> announced its third quarter financial results for the fiscal year ending December 2024, with revenue increasing by 7.3% year-on-year to 3 trillion 236.1 billion 11 million yen, operating profit increasing by 14.4% to 296.6 billion 38 million yen. The gross profit margin increased by 0.8 points from the same period last year to 47.8%, due to cost reductions and favorable product mix, with gross profit also increasing by 7.1% year-on-year to 516.4 billion yen. [Positive evaluation] Takeda Pharmaceuticals Mid-Term <4502> | <7735> S